title: Cyp1b1 exerts opposing effects on intestinal tumorigenesis via exogenous and endogenous substrates.
abstract: Cytochrome P450 1B1 (Cyp1b1) metabolism contributes to physiologic functions during embryogenesis but also to carcinogenic activation of polycyclic aromatic hydrocarbons (PAH). We generated Cyp1b1-deficient mice carrying the Min allele of the adenomatous polyposis coli gene. These Cyp1b1-deficient Min mice developed twice as many tumors as Min controls, which, however, remained similar in size and histology. Tumors from older (130 days) Cyp1b1-deficient Min mice selectively exhibited focal areas of nuclear atypia associated with less organized epithelia. The metabolism of endogenous substrates by Cyp1b1, therefore, suppresses tumor initiation but also affects progression. Treatment of Min mice with 7,12-dimethylbenzanthracene (DMBA) doubled both tumor multiplicity and size within 20 days but not when mice lacked Cyp1b1. This was paralleled by an abnormal staining of crypts with beta-catenin, phospho-IkappaB kinase, and RelA, which may represent an early stage of tumorigenesis similar to aberrant crypt formation. Cyp1b1 deletion did not affect circulating DMBA and metabolites. Cyp1b1 expression was higher in the tumors compared with normal small intestines. Increased tumorigenesis may, therefore, arise from generation of DMBA metabolites by Cyp1b1 in the developing tumors. Benzo(a)pyrene (BP), which is similarly activated by Cyp1b1 in vitro, did not affect tumorigenesis in Min mice. By contrast, BP and DMBA each suppressed tumor multiplicity in the absence of Cyp1b1. Cyp1b1 metabolism of DMBA and endogenous oxygenation products may each affect a tumor-promoting nuclear factor-kappaB activation, whereas Ah receptor activation by PAH affects suppression. Tumorigenesis may, therefore, depend on activation of PAH by Cyp1b1 and on offsetting suppression by Cyp1b1 of endogenous tumor-enhancing substrates.
authors.affiliation: Department of Pharmacology, University of Wisconsin, Madison, Wisconsin 53706, USA.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Halberg
authors.forename: Michele Campaigne
authors.initials: MC
authors.lastname: Larsen
authors.forename: Tammy L
authors.initials: TL
authors.lastname: Elmergreen
authors.forename: Alex Y
authors.initials: AY
authors.lastname: Ko
authors.forename: Amy A
authors.initials: AA
authors.lastname: Irving
authors.forename: Linda
authors.initials: L
authors.lastname: Clipson
authors.forename: Colin R
authors.initials: CR
authors.lastname: Jefcoate
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000493:pharmacokinetics; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases / Q000172:deficiency / Q000378:metabolism*; D001564:Benzo(a)pyrene / Q000493:pharmacokinetics; D002273:Carcinogens / Q000493:pharmacokinetics*; D065633:Cytochrome P-450 CYP1B1; D005260:Female; D051550:I-kappa B Kinase / Q000378:metabolism; D007414:Intestinal Neoplasms / Q000139:chemically induced / Q000201:enzymology* / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D000069463:Olive Oil; D010766:Phosphorylation; D010938:Plant Oils / Q000493:pharmacokinetics; D051996:Transcription Factor RelA / Q000378:metabolism; D051176:beta Catenin / Q000378:metabolism
chemical_list: D002273:Carcinogens; D000069463:Olive Oil; D010938:Plant Oils; C498144:Rela protein, mouse; D051996:Transcription Factor RelA; D051176:beta Catenin; D001564:Benzo(a)pyrene; D015127:9,10-Dimethyl-1,2-benzanthracene; D001189:Aryl Hydrocarbon Hydroxylases; C585498:Cyp1b1 protein, mouse; D065633:Cytochrome P-450 CYP1B1; D051550:I-kappa B Kinase
references.citation: Cell. 2004 Aug 6;118(3):285-96
references.pmid: 15294155
references.citation: Cancer Detect Prev. 2005;29(6):562-9
references.pmid: 16289386
references.citation: Cancer Res. 2003 Aug 15;63(16):4872-7
references.pmid: 12941808
references.citation: Anticancer Res. 2004 Sep-Oct;24(5A):2595-9
references.pmid: 15517863
references.citation: Nat Genet. 1997 Sep;17(1):88-91
references.pmid: 9288104
references.citation: Cell. 1990 Jun 1;61(5):759-67
references.pmid: 2188735
references.citation: Genome Biol. 2007;8(7):R131
references.pmid: 17615082
references.citation: Drug Metab Rev. 2006;38(1-2):337-52
references.pmid: 16684663
references.citation: Toxicol Appl Pharmacol. 2006 May 15;213(1):18-26
references.pmid: 16226778
references.citation: Free Radic Biol Med. 2008 Feb 15;44(4):570-83
references.pmid: 17997381
references.citation: Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8977-81
references.pmid: 8415640
references.citation: Cancer Res. 2001 Dec 1;61(23):8435-40
references.pmid: 11731424
references.citation: Clin Cancer Res. 2005 May 15;11(10):3758-65
references.pmid: 15897573
references.citation: Cancer Res. 2006 Aug 1;66(15):7571-7
references.pmid: 16885356
references.citation: J Biol Chem. 1996 Nov 8;271(45):28324-30
references.pmid: 8910454
references.citation: Toxicol Appl Pharmacol. 2006 Nov 1;216(3):469-78
references.pmid: 16893557
references.citation: Oncogene. 2006 Dec 4;25(57):7512-21
references.pmid: 17143295
references.citation: Development. 2007 Apr;134(7):1369-83
references.pmid: 17329364
references.citation: Carcinogenesis. 2003 Feb;24(2):327-34
references.pmid: 12584184
references.citation: Cancer Res. 1995 Oct 1;55(19):4479-85
references.pmid: 7671263
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9769-73
references.pmid: 15210940
references.citation: J Biol Chem. 1994 May 27;269(21):14905-11
references.pmid: 8195121
references.citation: Carcinogenesis. 2005 Mar;26(3):587-95
references.pmid: 15579483
references.citation: Cancer Res. 1997 Jul 15;57(14):3026-31
references.pmid: 9230218
references.citation: Carcinogenesis. 2006 Jun;27(6):1204-13
references.pmid: 16387742
references.citation: Mol Cancer Res. 2006 Mar;4(3):135-50
references.pmid: 16547151
references.citation: J Cell Sci. 1996 Nov;109 ( Pt 11):2619-25
references.pmid: 8937980
references.citation: Nat Rev Immunol. 2005 Oct;5(10):749-59
references.pmid: 16175180
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9530-5
references.pmid: 12886021
references.citation: J Immunol. 2008 Feb 15;180(4):2588-99
references.pmid: 18250470
references.citation: Cancer Res. 2006 Sep 15;66(18):9090-8
references.pmid: 16982751
references.citation: Proc Natl Acad Sci U S A. 2005 May 10;102(19):6960-5
references.pmid: 15870186
references.citation: Mutat Res. 1999 Jul 15;443(1-2):139-47
references.pmid: 10415437
references.citation: Science. 2003 Mar 7;299(5612):1578-81
references.pmid: 12624268
references.citation: J Immunol. 2007 Sep 1;179(5):2681-5
references.pmid: 17709478
references.citation: Am J Pathol. 2007 Mar;170(3):855-64
references.pmid: 17322371
references.citation: Genes Dev. 2004 Jun 15;18(12):1385-90
references.pmid: 15198980
references.citation: Toxicol Appl Pharmacol. 2005 Feb 1;202(3):244-57
references.pmid: 15667830
references.citation: Oncogene. 2004 Nov 25;23(55):8992-6
references.pmid: 15480419
references.citation: Cancer Metastasis Rev. 2007 Dec;26(3-4):503-24
references.pmid: 17943411
references.citation: Arch Biochem Biophys. 1997 Nov 15;347(2):181-92
references.pmid: 9367523
references.citation: Chem Res Toxicol. 2007 Mar;20(3):489-96
references.pmid: 17291012
references.citation: Stem Cell Rev. 2006;2(3):203-12
references.pmid: 17625256
references.citation: Mutat Res. 2006 Apr 30;604(1-2):60-70
references.pmid: 16574467
references.citation: Drug Metab Dispos. 2003 Nov;31(11):1346-51
references.pmid: 14570766
references.citation: J Clin Invest. 2007 Jul;117(7):1940-50
references.pmid: 17607366
references.citation: J Biol Chem. 1994 May 6;269(18):13092-9
references.pmid: 8175734
references.citation: Chem Res Toxicol. 2004 Dec;17(12):1667-74
references.pmid: 15606143
references.citation: Carcinogenesis. 2000 Aug;21(8):1567-72
references.pmid: 10910960